The FDA has ordered BioNTech to immediately halt its Phase I/II trial of malaria vaccine candidate BNT165e, pending changes.

FP008 is designed for patients with solid tumors that have not responded to existing immunotherapies targeting PD-1.

Income tax expense increased by $6.7 million in 2024 compared to 2023, primarily due to an increase in U.S. taxes under the ...

The investigational new drug application for Zabalafin Hydrogel for the treatment of mild to moderate atopic dermatitis has ...

NEW YORK, March 04, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully hu ...

The FDA approved the investigational new drug application for a phase 1 trial of ADCE-T02 in advanced solid tumors.

The FDA’s clinical hold has prompted a cautious response from investors, reflecting the heightened regulatory scrutiny that BioNTech now faces. The company’s immediate focus will be on resolving the ...

Discover 7 biotech companies in Taiwan, a rising regional player in precision medicine, immunotherapy, and drug development!

Gireesh Babu, New Delhi Wednesday, March 5, 2025, 14:45 Hrs [IST] With the registration of clinical research organisations (CROs) to b ...